PrEP with Tenofovir DF for Persons who Inject Drugs

Bangkok Tenofovir Study
PrEP with Tenofovir DF for Persons who Inject Drugs
Bangkok Tenofovir Study: Background


**Study Design: Bangkok Tenofovir Study**

- **Background**: Randomized, phase 3, double-blind, placebo-controlled trial conducted in Bangkok, Thailand that examined efficacy and safety of tenofovir DF as preexposure prophylaxis in persons who inject drugs.

- **Inclusion Criteria** (2,413 enrolled)
  - 20-60 years of age
  - HIV-1-negative
  - Reported injecting drugs in prior year
  - All subjects received risk-reduction counseling
  - All subjects received bleach and condoms
  - Excluded if HBsAg+
  - Excluded if pregnant or breastfeeding

- **Treatment Arms**:
  - Placebo: 1 pill daily
  - Tenofovir DF: 1 pill daily

**Study Design Diagram**

- Placebo (n = 1209)
- Tenofovir DF (n = 1204)
PrEP with Tenofovir DF for Persons who Inject Drugs
Bangkok Tenofovir Study: Background

2,413 HIV-Seronegative Persons who Inject Drugs

- Placebo
  (n = 1209)

- Tenofovir DF
  (n = 1204)

n = 1924 men

n = 489 women

Participants received directly observed therapy on average 87% of the time.

PrEP with Tenofovir DF for Persons who Inject Drugs
Bangkok Tenofovir Study: Results (Modified Intent-to-Treat)

This analysis does not include 2 additional HIV infections in placebo group that were identified at enrollment.
Follow-up time: mean 4.0 years (SD 2.1; max 6.9 years)

Interpretation: “In this study, daily oral tenofovir reduced the risk of HIV infection in people who inject drugs. Pre-exposure prophylaxis with tenofovir can now be considered for use as part of an HIV prevention package for people who inject drugs.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.